CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, synergistic apoptosis-inducing effects of asciminib and ponatinib were observed in CD34+/CD38− CML stem cells obtained from chronic phase and blast phase patients with the T315I gatekeeper mutation [143].